Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCOT: Adaptive Platform Trial for COVID-19
NCT04483960Phase 3Active, not recruiting
- Sponsor
- University of Melbourne
- Start
- Jul 2020
- Primary completion
- Jul 2025
- Modality
- Modified Peptides, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of nirmatrelvir + ritonavir, remdesivir in coronavirus disease 2019 (COVID-19), sponsored by University of Melbourne. Started Jul 2020; status: active, not recruiting.
02
Drugs
nirmatrelvir + ritonavirremdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04483960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483960.